The Hadassah Medical Center is launching a clinical trial to assess the safety and efficacy of the targeted drug, ribociclib, developed by Novartis. The trial led by Dr. Daniela Katz is intended for patients with non-operable liposarcoma.

International patients may apply at

https://clinicaltrials.gov/ct2/show/NCT02571829?term=ribociclib&rank=5